Oruka Therapeutics, Inc.
This is a multicenter, randomized, double-blinded, placebo-controlled clinical study of ORKA-002 in adult participants with moderate-to-severe HS.
The study will evaluate an induction dosing regimen of ORKA-002 administered every 4 weeks for 12 weeks compared with placebo during a double-blind induction period through Week 16. This will be followed by an open-label maintenance period, during which ORKA-002 will be administered every 12 weeks. The study will consist of four periods: * Screening Period * Induction Period (double-blind) * Maintenance Period (open-label) * Post-Treatment Follow-Up Period
Inclusion Criteria: 1. Has signs and symptoms of HS for at least 6 months; 2. Has HS lesions present in ≥ 2 distinct anatomic areas, one of which must be at least Hurley Stage II or III; 3. Has a history of inadequate response to systemic antibiotic treatment for HS, exhibited recurrence of HS symptoms after discontinuation of systemic antibiotics for HS, demonstrated intolerance to systemic antibiotics for HS, or has a contraindication to systemic antibiotics for HS Exclusion Criteria: 1. Presence of any other active skin disease or condition that may interfere with the assessment of HS; 2…
ORKA-002 administered by subcutaneous (SC) injection
Placebo administered by subcutaneous (SC) injection
Arctuva estimate
Verify or correct the compensation shown for this listing.